OCUMENSION THER.DL-00001
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glau… Read more
OCUMENSION THER.DL-00001 (5DG) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, OCUMENSION THER.DL-00001 (5DG) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
OCUMENSION THER.DL-00001 - Net Assets Trend (None–None)
This chart illustrates how OCUMENSION THER.DL-00001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for OCUMENSION THER.DL-00001 (None–None)
The table below shows the annual net assets of OCUMENSION THER.DL-00001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to OCUMENSION THER.DL-00001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
OCUMENSION THER.DL-00001 Competitors by Market Cap
The table below lists competitors of OCUMENSION THER.DL-00001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhengzhou Tiamaes Technology Co Ltd
SHE:300807
|
$249.56 Million |
|
Hua Yuan Property Co Ltd
SHG:600743
|
$249.61 Million |
|
BANKWELL FINANCIAL DL-01
F:33W
|
$249.68 Million |
|
Jiangsu Hongdou Industrial Co Ltd
SHG:600400
|
$249.75 Million |
|
Wajax Corporation
PINK:WJXFF
|
$249.54 Million |
|
Eve Holding Inc
NYSE:EVEX
|
$249.54 Million |
|
Vista Gold Corporation
NYSE MKT:VGZ
|
$249.52 Million |
|
Aura Biosciences Inc
NASDAQ:AURA
|
$249.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OCUMENSION THER.DL-00001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares OCUMENSION THER.DL-00001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently OCUMENSION THER.DL-00001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares OCUMENSION THER.DL-00001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OCUMENSION THER.DL-00001 (5DG) | €- | N/A | N/A | $249.54 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |